ArticleJournal of virology2002
Generation of hepatitis C virus-like particles by use of a recombinant vesicular stomatitis virus vector.
Article in Journal of virology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 71 citations in OpenAlex.
- Enhanced virus-specific CD8+ T cell responses by Listeria monocytogenes-infected dendritic cells in the context of Tim-3 blockade.PloS one · 2014Trial
- Optimal Expression, Function, and Immunogenicity of an HIV-1 Vaccine Derived from the Approved Ebola Vaccine, rVSV-ZEBOV.Vaccines · 2023Article
- Hepatitis C virus: Morphogenesis, infection and therapy.World journal of hepatology · 2018Review
- Development of an HIV vaccine using a vesicular stomatitis virus vector expressing designer HIV-1 envelope glycoproteins to enhance humoral responses.AIDS research and therapy · 2017Review
- Preclinical Development and Production of Virus-Like Particles As Vaccine Candidates for Hepatitis C.Frontiers in microbiology · 2017Review
- Article
- The immune response to a vesicular stomatitis virus vaccine vector is independent of particulate antigen secretion and protein turnover rate.Journal of virology · 2012Article
- Vesicular stomatitis virus as a vector to deliver virus-like particles of human norovirus: a new vaccine candidate against an important noncultivable virus.Journal of virology · 2011Article
- A vesicular stomatitis virus-based hepatitis B virus vaccine vector provides protection against challenge in a single dose.Journal of virology · 2010Article
- Characterization of hepatitis C virus core protein multimerization and membrane envelopment: revelation of a cascade of core-membrane interactions.Journal of virology · 2009Article
- Article
- Antigen delivery systems for veterinary vaccine development. Viral-vector based delivery systems.Vaccine · 2008Review
- Critical role of virion-associated cholesterol and sphingolipid in hepatitis C virus infection.Journal of virology · 2008Article
- Molecular biology of hepatitis C virus.Journal of gastroenterology · 2007Review
- Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector.Springer seminars in immunopathology · 2006Review
- Evaluating replication-defective vesicular stomatitis virus as a vaccine vehicle.Journal of virology · 2006Article
- Membrane binding properties and terminal residues of the mature hepatitis C virus capsid protein in insect cells.Journal of virology · 2004Article
- A candidate DNA vaccine elicits HCV specific humoral and cellular immune responses.World journal of gastroenterology · 2004Article
- Involvement of a bovine viral diarrhea virus NS5B locus in virion assembly.Journal of virology · 2004Article
- Unique features of hepatitis C virus capsid formation revealed by de novo cell-free assembly.Journal of virology · 2004Article
Corrections and comments
- Commented on by
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis C virus (HCV), a major etiologic agent of hepatocellular carcinoma, presently infects approximately 400 million people worldwide, making the development of protective measures against HCV infection a key objective. Here we have generated a recombinant vesicular stomatitis virus (VSV), which expresses the HCV structural proteins, by inserting the contiguous Core, E1, and E2 coding region of HCV into the VSV genome. Recombinant VSV expressing HCV Core, E1, and E2 (VSV-HCV-C/E1/E2) grew to high titers in vitro and efficiently expressed the incorporated HCV gene product, which became fully processed into the individual HCV structural proteins. Biochemical and biophysical analysis indicated that the HCV Core, E1, and E2 proteins assembled to form HCV-like particles (HCV-LPs) possessing properties similar to the ultrastructural properties of HCV virions. Mice immunized with VSV-HCV-C/E1/E2 generated cell-mediated immune responses to all of the HCV structural proteins, and humoral responses, particularly to E2, were also readily evident. Our data collectively indicate that engineered VSVs expressing HCV Core, E1, and E2 and/or HCV-LPs represent useful tools in vaccine and immunotherapeutic strategies designed to address HCV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.